<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">PRIMIDONE</span><br/>(pri'mi-done)<br/><span class="topboxtradename">Apo-Primidone <img border="0" src="../images/maple.gif"/>, </span><span class="topboxtradename">Mysoline<br/></span><b>Classifications:</b> <span class="classification">central nervous system agent</span>; <span class="classification">barbiturate, anticonvulsant</span><br/><b>Prototype: </b>Phenobarbital<br/><b>Pregnancy Category: </b>D<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>50 mg, 250 mg tablets; 250 mg/5 mL suspension</p>
<h1><a name="action">Actions</a></h1>
<p>Closely related chemically to barbiturates and with similar mechanism of action. Converted in body to phenobarbital. Impairs
         vitamin D, calcium, folic acid, and vitamin B<sub>12</sub> metabolism and utilization.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Antiepileptic properties result from raising the seizure threshold and changing seizure patterns.</p>
<h1><a name="uses">Uses</a></h1>
<p>Alone or concomitantly with other anticonvulsant agents in the prophylactic management of complex partial (psychomotor) and
         generalized tonic-clonic (grand mal) seizures.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Essential tremor.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to barbiturates, porphyria. Safety during pregnancy (category D) or lactation is not established.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Chronic lung disease; liver or kidney disease; hyperactive children.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Seizures</span><br/><span class="rdage">Adult/</span><span class="rdage">Child:</span> <span class="rdroute">PO</span> <img src="../images/special/greaterorequal.gif"/><i>8 y</i>, 250 mg/d, increased by 250 mg/wk (max: 2 g in 24 divided doses)<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> 8 y, 125 mg/d, increased by 125 mg/wk (max: 2 g/d in 24 divided doses)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give whole or crush with fluid of patient's choice.</li>
<li>Give with food if drug causes GI distress.</li>
<li>
            				Note: Transition from another anticonvulsant to primidone normally requires at least 21 wk.
            			
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span>
<span class="speceff-common">Drowsiness, sedation, vertigo, ataxia, headache,</span> excitement (children), confusion, unusual fatigue, hyperirritability, emotional disturbances, acute psychoses (usually patients
      with psychomotor epilepsy). <span class="typehead"> Special Senses:</span>  Diplopia, nystagmus, swelling of eyelids. <span class="typehead"> GI:</span>
<span class="speceff-common">Nausea, vomiting, anorexia.</span>
<span class="typehead">Hematologic:</span> Leukopenia, thrombocytopenia, eosinophilia, decreased serum folate levels, megaloblastic anemia (rare). <span class="typehead">Skin:</span> Alopecia, maculopapular or morbilliform rash, edema, lupus erythematosus-like syndrome. <span class="typehead">Urogenital:</span> Impotence. <span class="typehead">Body as a Whole:</span> Lymphadenopathy, osteomalacia. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Alcohol,</b>
<span class="classification">cns depressants</span> compound CNS depression; <b>phenobarbital</b> may decrease absorption and increase metabolism of <span class="classification">oral anticoagulants</span>; increases metabolism of <span class="classification">corticosteroids</span>, <span class="classification">oral contraceptives</span>, <span class="classification">anticonvulsants</span>, <b>digitoxin,</b> possibly decreasing their effects; <span class="classification">antidepressants</span> potentiate adverse effects of primidone; <b>griseofulvin</b> decreases absorption of primidone. <span class="typehead">Herbal:</span>
<b>Kava-kava,</b>
<b>valerian</b> may potentiate sedation. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Approximately 6080% absorbed from GI tract. <span class="typehead">Peak:</span> 4 h. <span class="typehead">Distribution:</span> Distributed into breast milk. <span class="typehead">Metabolism:</span> Metabolized in liver to phenobarbital and PEMA. <span class="typehead">Elimination:</span> Excreted in urine. <span class="typehead"> Half-Life:</span> Primidone 324 h, PEMA 2448 h; phenobarbital 72144 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Perform baseline and periodic CBC, complete blood chemistry (q6mo), and primidone blood levels. (Therapeutic blood
            level for primidone: 510 mcg/mL.)
         </li>
<li>Monitor primidone plasma levels (concentrations of primidone &gt;10 mcg/mL are usually associated with significant ataxia and
            lethargy).
         </li>
<li>Therapeutic response may not be evident for several weeks.</li>
<li>Observe for S&amp;S of folic acid deficiency: Mental dysfunction, psychiatric disorders, neuropathy, megaloblastic anemia. Determine
            serum folate levels if indicated.
         </li>
<li>Be aware that presence of unusual drowsiness in breast fed newborns of primidone-treated mothers is an indication to discontinue
            breast feeding.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Avoid driving and other potentially hazardous activities during beginning of treatment because drowsiness, dizziness, and
            ataxia may be severe. Symptoms tend to disappear with continued therapy; if they persist, dosage reduction or drug withdrawal
            may be necessary.
         </li>
<li>Avoid alcohol and other CNS depressants unless otherwise directed by physician.</li>
<li>Do not take OTC medications unless approved by physician.</li>
<li>Pregnant women should receive prophylactic vitamin K therapy for 1 mo prior to and during delivery to prevent neonatal hemorrhage.</li>
<li>Withdraw primidone gradually to avoid precipitating status epilepticus.</li>
<li>Carry medical information at all times. It needs to indicate medical diagnosis, medication(s), physician's name(s), address(es),
            and telephone number(s).
         </li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>